S

Simply Better Brands Corp
XTSX:SBBC

Watchlist Manager
Simply Better Brands Corp
XTSX:SBBC
Watchlist
Price: 0.91 CAD 1.11% Market Closed
Market Cap: 97.5m CAD

Relative Value

SBBC doesn't have a meaningful market cap.

The Relative Value of one SBBC stock under the Base Case scenario is 0.48 CAD. Compared to the current market price of 0.91 CAD, Simply Better Brands Corp is Overvalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SBBC Relative Value
Base Case
0.48 CAD
Overvaluation 47%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
31
vs Industry
56
Median 3Y
0.5
Median 5Y
0.7
Industry
2.4
Forward
1.4
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-4.1
Industry
20.3
Forward
-21.7
vs History
vs Industry
19
Median 3Y
-9.7
Median 5Y
-15.2
Industry
15.6
vs History
vs Industry
Median 3Y
-6.5
Median 5Y
-5.3
Industry
23.1
vs History
19
vs Industry
5
Median 3Y
2
Median 5Y
1.8
Industry
2
vs History
31
vs Industry
56
Median 3Y
0.6
Median 5Y
0.8
Industry
2.5
Forward
1.4
vs History
31
vs Industry
50
Median 3Y
1
Median 5Y
1.2
Industry
4.8
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-13.2
Industry
12.5
Forward
27.6
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-9.4
Industry
15.7
vs History
vs Industry
16
Median 3Y
-12.4
Median 5Y
-22.3
Industry
14.1
vs History
vs Industry
16
Median 3Y
-12.4
Median 5Y
-18.6
Industry
17.6
vs History
41
vs Industry
11
Median 3Y
3
Median 5Y
5.8
Industry
1.8

Multiples Across Competitors

SBBC Competitors Multiples
Simply Better Brands Corp Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Simply Better Brands Corp
XTSX:SBBC
97.5m CAD 1.6 -8.1 -45.2 -19.7
US
Eli Lilly and Co
NYSE:LLY
778.5B USD 15.9 70.1 37.6 41.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.9 19.8 13 14.8
CH
Roche Holding AG
SIX:ROG
217B CHF 3.6 26.3 9.8 11.5
UK
AstraZeneca PLC
LSE:AZN
167.3B GBP 4 28.6 130.9 197.4
CH
Novartis AG
SIX:NOVN
182.6B CHF 4.2 17.2 10.2 13.6
US
Merck & Co Inc
NYSE:MRK
209.4B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
121.1B EUR 1.3 9.6 5.2 6.2
P/E Multiple
Earnings Growth PEG
CA
S
Simply Better Brands Corp
XTSX:SBBC
Average P/E: 25.1
Negative Multiple: -8.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
70.1
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.8
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.3
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.6
36%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.6
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
S
Simply Better Brands Corp
XTSX:SBBC
Average EV/EBITDA: 433.5
Negative Multiple: -45.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.6
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
CH
Novartis AG
SIX:NOVN
10.2
5%
2
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
S
Simply Better Brands Corp
XTSX:SBBC
Average EV/EBIT: 1 866.9
Negative Multiple: -19.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.1
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
197.4
21%
9.4
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.2
14%
0.4